SCHEMBL8632

SCHEMBL8632

CCCc1oc2ccc(Br)cc2c(=O)c1-c1cccc(F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 10/20 0.54
GABRD O14764 10/20 0.54
GABRA1 P14867 10/20 0.54
GABRB1 P18505 10/20 0.54
GABRG2 P18507 10/20 0.54
GABRB3 P28472 10/20 0.54
GABRA5 P31644 10/20 0.54
GABRA3 P34903 10/20 0.54
GABRA2 P47869 10/20 0.54
GABRB2 P47870 10/20 0.54
GABRA4 P48169 10/20 0.54
GABRE P78334 10/20 0.54
GABRA6 Q16445 10/20 0.54
GABRG1 Q8N1C3 10/20 0.54
GABRG3 Q99928 10/20 0.54
GABRQ Q9UN88 10/20 0.54
MAPT P10636 4/20 0.40
TP53 P04637 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9107 0.91 GABRP (0.56) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8168 0.88 GABRP (0.52) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL9138 0.87 GABRP (0.49) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8108 0.86 GABRP (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL11500 0.83 TNKS (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8932 0.82 GABRP (0.51) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8856 0.82 GABRA1 (0.53) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8059 0.81 GABRP (0.53) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL15528285 0.80 GABRP (0.51) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL9273 0.79 GABRP (0.53) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US claimed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 EP claimed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 EP claimed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 EP claimed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US claimed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 WO claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
WO-2023130334-A1 METHOD FOR PREPARING CHROMEN-4-ONE COMPOUND AND INTERMEDIATE THEREOF 同润生物医药(上海)有限公司 2023-07-13 WO disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 EP disclosed
EP-2496567-B1 NOVEL BENZOPYRAN KINASE MODULATORS RHIZEN PHARMACEUTICALS S A (CH) 2017-07-12 EP disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 EP disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 GABRP 1434/4885GABRD 2656/4885GABRA1 2758/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRP 1342/4885GABRD 2739/4885GABRA1 3106/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRP 1342/4885GABRD 2739/4885GABRA1 3106/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRP 1342/4885GABRD 2739/4885GABRA1 3106/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRP 1342/4885GABRD 2739/4885GABRA1 3106/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A GABRP 2530/4885GABRD 4049/4885GABRA1 3473/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRP 1342/4885GABRD 2739/4885GABRA1 3106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.